Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN HF 8 versus CLINIMIX E 5 20 SULFITE FREE W ELECT IN 20 DEXTROSE W CALCIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN HF 8 versus CLINIMIX E 5 20 SULFITE FREE W ELECT IN 20 DEXTROSE W CALCIUM IN PLASTIC CONTAINER.
AMINOSYN-HF 8% vs CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn-HF 8% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, promoting nitrogen balance and tissue repair in patients unable to tolerate oral intake.
Parenteral nutrition providing essential amino acids, electrolytes, and dextrose for caloric support and protein synthesis.
1-2 g/kg/day intravenously as total parenteral nutrition, typically administered as a continuous infusion over 24 hours.
Intravenous. Adult: 2 L/day (providing 100 g protein and 400 g dextrose) or as per metabolic needs. Rate: 100 mL/hr initially, adjusted based on tolerance and glucose monitoring.
None Documented
None Documented
Not applicable as amino acids are rapidly cleared; terminal half-life of infused amino acids is approximately 10-30 minutes.
Amino acids: 0.5-2 hours (rapid clearance dependent on metabolic demand). Glucose: ~2-4 hours in euglycemic states. No single terminal half-life due to mixture.
Renal: >90% as amino acids and metabolites; fecal: <5%.
Components are primarily metabolized; nitrogen waste excreted renally as urea (85-90%), with minimal biliary/fecal elimination (<5%). Electrolytes and dextrose are fully metabolized or excreted renally.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution